Skip to main content
LKFT $33.49 +0.30%
LKFT · Lakefront Biotherapeutics NV
Track LKFT — free
$33.49 +0.10 (+0.30%) Play latest call Q1 2026 earnings call transcript
Market Cap
$2.20B
Shares
65.90M
Volume · Nov 20 38.91K Avg daily vol (3M) 281.53K
All webcasts

Conference · 2026-11-17

Lakefront Biotherapeutics NV (LKFT) November 17, 2026 Conference Transcript

Concluded Nov 17, 2026 Audio replay
Nov 17, 2026 24:40 35 turns
Period
2026-11-17
Runtime
24:40
Sources
2 artifacts

Transcript & audio

24:40 Audio
Sian Hamer Analyst — Jefferies

Hi, everyone. Welcome to the Jefferies Healthcare Conference. I'm Sian Hammer from the European Pharma and Biotech Team here at Jefferies, and I'm very lucky to be joined by Lakefront Biotherapeutics. So we have the CEO, Henry Gozerbruch, we have the CFO, Aaron Cox, and we have the CMO, Eric Hendrick. Thank you very much for joining us. Perhaps with some introductory questions, it's been a very transformative last 12 months for the company. For investors who may not have followed Lakefront, how do you compare the company that exists today versus a couple of years ago?

Great. Well, first of all, we're delighted to be here. Thanks for having us back. Good to be back at Jefferies London. So, we're just a completely different company than we were a year ago. So, a year ago, I was here representing Galapagos. We, at that point, had a pipeline of cell therapy programs that was We're burning about $300 million a year. We did not believe that that pipeline had any commercial future. We had an existing relationship with Gilead, and we were really just beginning to start the process of speaking with the unions and works councils on the potential wind down of cell therapy. So that's where we were last year. Now we're back. We're Lakefront. We have an exciting portfolio of T-cell engagers. We have a new senior team. We've managed the cash very aggressively and positively, and it's going to be an exciting six months of additional data releases and moving forward in our clinical programs, and the cell therapy programs have been substantially gone down at this point, so a very, very different picture than a year ago.

Sian Hamer Analyst — Jefferies

Thanks very much. Let's just jump through into Gamgertamig, which is arguably your most important asset. So in June, of course, Lakefront and Gilead completed the acquisition of Oro Medicines, and you have this BCMA CD3 Gamgertamig in your portfolio. Having now had the opportunity to sort of review the data set and integrate the team, what has increased your conviction since signing this deal?

So we're very pleased with how the clinical data is performing. We had seen a lot of clinical data when we did the deal. That was both investigator-initiated studies as well as early data from the company-sponsored studies. We were accepted at ASH to have a poster presentation, and we just press-released the ASH abstract, which reflect the data from over the summer. But, of course, since then, the data has continued to mature further. So it is coming in exactly as we hoped it would, with a very attractive immune reset profile, and we think a very significant step forward for patients in these diseases. And as I said, we're excited to expand the program and try to bring that to patients as soon as possible.

Sian Hamer Analyst — Jefferies

Thank you very much. If we actually just touch on the ASH abstract, what should investors keep in mind when looking at the ASH abstract, and what could change, other than maturity, of course, and perhaps increased follow-up, when looking at the actual data at ASH?

Eric Hedrick Other

Yeah, I think when looking at the abstract itself and then the presentation of the ASH, again, as Henry mentioned, this is an immune reset therapy, so sort of inherent to that sort of therapy. You need a couple of steps to actually fulfill the criteria for having an immune reset. Uh, effect or response. Um, you know, the first step is that your molecule needs to provide sufficient depletion of B cells and plasma cells. Um, we've established now over a number of different doses that we can have that effect. During that period of immune cell depletion, um, we've seen very robust responses, remissions, uh, happen almost uniformly. So these are all necessary steps, but ultimately what you need to see is with longer follow-up, and particularly after the immune system reconstitutes, that hopefully the remissions will remain. So there's a lot of sort of, I think, different versions of immune reset being floated out there now. That would be one clinical definition of relevance, that you have a sustained remission following B cell and plasma cell reconstitution. And in the ASH abstract, you see that the majority of patients who were able to achieve a response during the period of immune cell depletion retain that response even when the immune system reconstitutes. So we feel as though with more mature data, we're sort of checking the boxes in terms of describing an immune reset type of effect. And like Henry mentioned, so far with maturity of this company-sponsored trial data, we're happy with what we're seeing.

Sian Hamer Analyst — Jefferies

Thank you very much. I would argue that autoimmune diseases still remains a pretty white space. There's still a lot to do in that area. What is it about BCMA CD3 targeting that you believe is an attractive modality for autoimmune diseases?

Eric Hedrick Other

Yeah, we were attracted to BCMA as a target. Because of some sort of transformation, recent understanding of BCMA, and so BCMA historically was thought to be restricted to plasma cells, you know, and hence, you know, led to its use approval in the setting of multiple myeloma. I think more recently we realized that BCMA can be expressed further down in the B cell maturation lineage, down to the naive B cell stage. And so what we see... With our BCMA-directed T cell engager is actually depletion, not only of plasma cells, but B cells as well, and obviously for diseases where autoantibodies are an important, you know, pathogenic factor, you want to be able to eliminate plasma cell activity. That's where the autoantibodies are stemming from. And so that's what interested us in BCMA as a target, CD19, which is the other target within the immune reset field. It has some value as well, almost certainly, but, you know, what attracted us to BCMA was the fact that you were able to deplete both cell populations that were involved in autoantibody-associated immune diseases.

Yeah, and to your point, I mean, there's a lot still to do in autoimmune diseases. We were attracted to this program, so we think it has potential in maybe as many as 20 diseases with a really unique profile And an opportunity to really meaningfully move to standard of care for patients in those diseases. So we absolutely agree there's a lot of white space in autoimmune diseases.

Sian Hamer Analyst — Jefferies

Yeah, and just off the back of that, actually, is there potential for GamGear to be more of a platform asset as opposed to just for WAIHA and ITP?

Absolutely. So you'll see us, as we've publicly stated, you'll see us expand pretty rapidly this upcoming year. So we've announced two basket studies of a broad set of diseases, both in neuroindications and endocrine indications. And then there'll be, you know, additional opportunities down the road as well. So yes, we very much see this as a program that can have a very expanded clinical program. But what also is very attractive is that these studies are pretty small, all things considered. The effect is so significant, we really don't need many patients to prove that there's utility in a number of different diseases. So we like that from a capital perspective, they're very efficient, they're quick to market, and those are all attractive features as well.

Sian Hamer Analyst — Jefferies

Very clear. When we think about the current autoimmune treatment paradigm, of course you have CD19, CAR-T's, you have CD20s, but perhaps they're not really addressing the sort of key underlying disease for these patients. So where do you think the BCMA targeting ultimately sits within that treatment paradigm when thinking of it more commercially?

Eric Hedrick Other

Yeah, I would say the hope in general, you know, if you look at, you know, take ITP, which is probably an early indication at this point. There's lots of treatments out there. They were effective, you know, in some way or another. What the field lacks is a treatment that actually, you know, eliminates or eradicates the disease activity, right? So ITP is a good example of a, you know, chronic autoimmune disease where, you know, there are... effective drugs of some sort, but they're all chronically administered. The idea here is to give a short course limited treatment and actually induce a treatment-free remission, and that idea of a treatment-free remission with durability that's sufficiently long is something that's missing from the arsenal of treatments for autoimmune disease right now, and that's really the aim of a treatment like amgertamik.

Sian Hamer Analyst — Jefferies

Understood. Thanks very much for that. You've indicated that registrational development could begin as early as 2027 in both ITP and WAIHA. What remaining questions do you still need answered before fully committing to those studies and actually getting them ahead?

Eric Hedrick Other

I would say we're a long way towards planning and hopefully initiating those studies next year. We'll obviously have to have discussions with regulators around the design of those trials, which we intend on doing. I would say that a lot of pieces of the puzzle in terms of what you need to design phase three are already in place. We feel that we're in a good place with the treatment regimen, with the dose, with understanding the level of activity we're seeing in relation to the primary endpoint of those studies. One I think, you know. Factor that will follow closely along with these remissions is the durability issue of these remissions. We don't think that's a limitation, though, if that's a not-yet-solved question. That really doesn't factor into the Phase III designs in our interpretation of those designs. And so obviously, you know, with more follow-up, we'll be more interested in seeing the true durability of these remissions. But that's different than knowing what we need to have in place to go into phase three, and we think we're basically there.

Sian Hamer Analyst — Jefferies

Understood. The other interesting thing, and the thing we get a few questions about from investors is, I mean, shortly after the ORO transaction, you had UCB acquiring Candid Therapeutics, and that sort of effectively endorsed the BCMA direct depletion as an autoimmune strategy as well. Has anything you've seen from competitor programs reinforced or changed your view on the opportunity?

No, it's really the short answer, I mean, we did some pretty in-depth diligence on all the other programs, not just BCMA, but some of the other approaches, and again, it's playing out the way we had anticipated. What we really liked about the ORO programs that we acquired is that they were first in class with a multiple year advantage in those diseases, and so, you know, some of the other sponsors have approached more competitive diseases with, you know, with more existing options. But the oral programs are really focused on places where the competitive intensity is less and where there's just a very exquisite relationship between B cell depletion and patient impact ultimately. And so none of that has changed. Look, we would not be surprised to see... More competition coming into it, and we welcome that, so I think we're quite well positioned, having already established a good dosing regimen, safety, and, of course, demonstrated now clinical efficacy and safety for patients, so I think we're far ahead of some of those new folks coming in, but, look, it's going to be an attractive space, and we welcome competition.

Sian Hamer Analyst — Jefferies

Got it. You also have three preclinical autoimmune programs that came with the oral acquisition. What are the expected development candidate and IND timelines? Is there anything you can reveal to us or tell us about the thinking regarding those preclinical assets?

So we're quite excited about the preclinical programs, since they represent really a good mix of some known targets and some more novel approaches. But at this point, we'd like to really keep the focus on gemgertemic. That is the first advanced program, as we talked about, ready to go into registration studies. I think there'll be a point next year where we'll share a little bit more about the preclinical programs, and we'll make that a part of our story. But I think at this point, there's a lot to talk about with Gomgertamig, and we'd like to keep the focus on that.

Sian Hamer Analyst — Jefferies

Very clear. And of course, you have a very important strategic partnership with Gilead. How does that relationship work between Lakefront and Gilead, particularly as it comes to the ORO programs?

So one of the big focus areas of this past year was really to change that relationship. So Gilead is a valued partner, but Gilead had specific opt-in rights where they could at a sort of a discounted value opt-in to any POC program that we as a company have or would acquire or would build. And so obviously that was a challenging situation to be in when you're starting over and you're trying to bring in a new portfolio. So when we did the Oro deal, we in parallel negotiated with Gilead, and we came to a really good arrangement where they, instead of paying us $150 million, they paid for half the transaction. They're paying for half the R&D going into it. They will be the commercialization partner, so we avoid any, you know, medical affairs, marketing, you know, commercial investments. We are just responsible in partnership with them in the 50-50 partnership to pay for the R&D, and then we get a nice royalty on the back end. So we're very happy with how we moved that. Important to understand is on the preclinical programs, we actually agreed on a 50-50 profit split all the way through to commercialization. And certainly that would be more the model of any future deal if there was another deal. And that would be more the model we would aim to achieve. So again, we're happy they're a valued partner. We look forward to seeing what they can do once the clinical program is expanded and we're in registration studies in terms of, you know, accelerating the program and just putting, you know, their muscle and their firepower behind it. So we're pleased with how that's been reshaped over the last year.

Sian Hamer Analyst — Jefferies

Understood. If we speak a little bit about your financial position, so you've got it to roughly around 2 billion euros of year-end cash, and that leaves at least 1.6 billion remaining even after funding the portfolio through first approval, which is a pretty unique position for a company like yourselves to be in, I would argue. You know, how does that change the strategic options available for Lakefront and potential investment strategies to continue growing the company?

Aaron Cox CFO

Yeah, we're certainly in a unique position as a biotech with presently 2.2 billion euros of cash on the balance sheet. Importantly, we also have a number of inflows coming in, which is also unique to biotech, and those comprise 20 to 25 million euros annually in royalties. We have about 125 million in aggregate of cash tax refunds that will be coming in over the next five years, and obviously interest income coming off of that 2.2 billion. And with all of that, it provides great strategic flexibility in terms of how do we want to deploy that capital? Do we want to sit on the sidelines and just fund our current portfolio? Do we want to go after potential new acquisitions, whether in partnership with Gilead or on our own? Importantly, with this ORO transaction, we did carve out $500 million of capital where we can do transactions independent of Gilead. And also, a part of that $500 million, we have a $150 million sublimit to return capital to shareholders, which we've done over the last several months. We completed a €50 million buyback in October, and yesterday we launched another €50 million buyback. But we certainly are in a great position with the cash on the balance sheet and enough cash to go out and do something outside of our current portfolio with that $1.6 billion that you mentioned.

Sian Hamer Analyst — Jefferies

Understood. And just on your last point, actually, you know, what is Lakefront and or Gilead really looking for in future assets outside of Gamga to make, you know, what therapeutic areas excite you, what modalities?

Yeah, look, we have... A wide aperture to some degree, but what we're looking for, similar to the oral portfolio, we want to look for very clear, you know, clinical proof of concept. So, you know, a significant amount of patient level efficacy and safety data. And that's what we had in the oral portfolio. Some of the other things I mentioned along the way already, having an ability to very time and capital efficiently move programs forward, so we're not looking for very large programs with lots of development dollars needed. That's kind of the history we came from, and we don't want to do that again. So these need to be either rare or underappreciated areas where, again, And you can very quickly come to a clinical program that can move you forward. Certainly, autoimmune indications are top of the list, given the portfolio we've established. But, you know, we're looking broadly. Now, that all being said, we love our current portfolio. We've got a lot to do, not just on Gumgurdemig, but the preclinical program. So, look, we're in no rush to, you know, to rush to the second deal. And, you know, we'll see what opportunities present themselves, but we'll be very, very financially disciplined as we were on the first deal, and so that will absolutely be another key guideline for us as we look at additional deals.

Sian Hamer Analyst — Jefferies

That's very, very clear. And then when we think about the next couple of years, should we expect cash burn to sort of inflect higher as you put Gemgur to make into registrational development? Or is the sort of current collaboration structure with Gilead strong enough to actually lower the costs associated with certain programs?

Aaron Cox CFO

Yeah, so how it's structured is Gilead, we will fund anything pre-registrational and then we'll split 50-50 costs with Gilead for registrational trials. So obviously the cost to both sides will be less than if we were individually funding them. We haven't given specific guidance on a year-by-year basis, but we did give that $1.6 billion remaining after funding the full potential of GAM, Gertemig, and our preclinical portfolio. And that's not just current indications. That could fund additional indications beyond the ones that we've already said publicly.

Sian Hamer Analyst — Jefferies

That's very, very clear. And then perhaps if we think a little bit about the key cutters to look out for over the next couple of years, you know, what should investors really be focusing on for Lakefront Biotherapeutics in terms of its value proposition?

Yeah, as I said, we were very pleased to have been accepted by ASH, and that acceptance press release unveiled for the first time sort of the tip of the iceberg of the clinical data that, you know, we got so excited about, so that was the starting point, so of course there'll be more detail at the actual ASH Congress, you know, more mature data, bigger, you know, bigger number of patients, et cetera, so that'll come up in, you know, about a month, and then early next year, Here, again, as I said, you'll see us expanding the clinical program and starting these basket studies. We do have a significant amount of investigator-initiated data that we've seen, but that we don't have publication rights. Now, we are aware of what these investigators are doing from a publication perspective. So you'll see some of that next year as well, and that'll further add to the body of clinical evidence. So, really, with the ASH abstract press release, we're entering a period of pretty heavy clinical data and then clinical execution milestones over the next six to nine months. And then the last piece will be these preclinical programs that will come in at some point next year. We'll talk about those a little bit as well.

Sian Hamer Analyst — Jefferies

Understood. Actually, just on those basket studies, so it's myositis, strogens, and pemphigus, if I remember correctly.

So that is a current basket study that's ongoing. I'm really talking more about new basket studies we'll initiate in the first half of next year. And neurologic diseases as well as endocrine diseases. And again, they will significantly expand the clinical program for and allow us to pursue many of these additional indications in a very capital effective way A, to then be in a position in the not-too-distant future to add additional registration programs to our broader program, which, of course, is very important just given what this medicine has the potential of doing. It'll also give us access to additional milestones from Gilead and, of course, a bigger pie of royalty income down the road. So it's something we're very focused on.

Sian Hamer Analyst — Jefferies

Of those current indications within the current basket study, is there one that you see the strongest rationale for with respect to BCMA?

Eric Hedrick Other

Yeah, I think it's a little bit difficult to answer that question. I think one of the things that we're facing is, you know, sort of the limits of our understanding of the real immunology behind some of these diseases. Again, this is a place where we feel like we have an advantage in having a BCMA-directed molecule because if it's... You know, purely autoantibody production by long-lived plasma cells, that should be addressed with BCMA. If it's more B-cell, T-cell interactions, you know, during the B-cell maturation phase that are, you know, in operation, then BCMA should address that cell population as well. Yeah, and honestly, one of the best ways to sort out the immunology of these diseases is It's treating patients with gamgertamig and seeing, you know, what their responses look like and what their durability looks like. But that's something that, you know, we'll sort of establish along the way as we do clinical trials.

Yeah, and that's, again, the elegance with these basket studies where we can simultaneously really have, you know, a large number of additional indications that we can assess. And, you know, given the profound impact that this program has on B cell depletion and ultimately, you know, patients and their quality of life. You know, it's not going to take many patients to really see efficacy and additional indications. So, you know, high single-digit, low double-digit number, maybe. So, again, it's a very effective way to really answer that question, not just theoretically, but, frankly, clinically. So, you know, we're quite delighted to start those studies early next year.

Sian Hamer Analyst — Jefferies

Understood. Any questions from the audience? Thank you very much for joining us. Thank you. Thanks, everybody.

Analyst Q&A · 1 question
Full-screen source Call document